home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

37.36 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

7 Biotech Stocks to Buy on the Dip: June 2024 ↗

June 24, 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

Via InvestorPlace

A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts ↗

June 21, 2024

Via Benzinga

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In ↗

May 14, 2024

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.

Via Benzinga

Topics Cannabis

Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript ↗

April 30, 2024

HRMY earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024 ↗

April 30, 2024

HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Key Takeaways From Harmony Biosciences Analyst Ratings ↗

April 30, 2024

Via Benzinga

Evaluating Harmony Biosciences: Insights From 8 Financial Analysts ↗

March 28, 2024

Via Benzinga

Analyst Ratings For Harmony Biosciences ↗

February 22, 2024

Via Benzinga

NASDAQ:HRMY stands out as a growth opportunity that won't break the bank. ↗

January 10, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:HRMY.

Via Chartmill

Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View ↗

April 30, 2024

Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with...

Via Benzinga

Topics Earnings

Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy

April 30, 2024

From Harmony Biosciences

Via GlobeNewswire

Updates: HRMY, MELI, SWAV ↗

February 28, 2024

Another day, another slew of quarterly update reports for our followed stocks.

Via Talk Markets

Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript ↗

February 22, 2024

HRMY earnings call for the period ending December 31, 2023.

Via The Motley Fool

Topics Earnings

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

February 22, 2024

From Harmony Biosciences

Via GlobeNewswire

A Glimpse Into The Expert Outlook On Harmony Biosciences Through 6 Analysts ↗

January 02, 2024

Via Benzinga

The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024 ↗

February 12, 2024

Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently.

Via InvestorPlace

The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024 ↗

February 07, 2024

Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks.

Via InvestorPlace

NASDAQ:HRMY: good value for what you're paying. ↗

January 25, 2024

In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Investors should take notice of NASDAQ:HRMY—it offers a great deal for the fundamentals it presents. ↗

January 03, 2024

Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

Why Harmony Biosciences Stock Got Slammed Today ↗

January 02, 2024

The commercial-stage company was dinged by a bearish new take from a researcher.

Via The Motley Fool

2023 Year In Review ↗

January 02, 2024

The S&P 500 had a strong year in 2023, returning about 24% to investors from the beginning of the year to the end. Some of that was a bounce back from a poor 2022 when it was down over 11%.

Via Talk Markets

Topics Stocks

NASDAQ:HRMY is showing good growth, while it is not too expensive. ↗

December 18, 2023

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) stands out as a growth opportunity that won't break the bank.

Via Chartmill

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar ↗

December 17, 2023

While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.

Via InvestorPlace

NASDAQ:HRMY, an undervalued stock with good fundamentals. ↗

December 13, 2023

When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

Russell 2000 Front-Runners: 3 Stocks to Keep an Eye On ↗

December 07, 2023

Although Russell 2000 stocks may operate in the lightweight category, these entities could potentially provide a knockout punch.

Via InvestorPlace

Looking for growth without the hefty price tag? Consider NASDAQ:HRMY. ↗

November 27, 2023

Investors seeking growth at a reasonable cost should explore HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY).

Via Chartmill

NASDAQ:HRMY is probably undervalued for the fundamentals it is displaying. ↗

November 22, 2023

HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable. ↗

November 03, 2023

Investors should take note ofHARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), a growth stock that remains attractively priced.

Via Chartmill

Quick Look At Reports From ServiceNow, Chipotle, And Harmony ↗

November 02, 2023

ServiceNow is a steady, reliable SaaS firm that continues to prove its value and growth potential to investors.

Via Talk Markets

NASDAQ:HRMY is an undervalued gem with solid fundamentals. ↗

November 01, 2023

For those who appreciate value investing, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a compelling option with its solid fundamentals.

Via Chartmill

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com